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In genome-wide association studies, only a subset of all genomic variants are typed by current, high-throughput, SNP-genotyping plat-
forms. However, many of the untyped variants can be well predicted from typed variants, with linkage disequilibrium (LD) information
among typed and untyped variants available from an external reference panel such as HapMap. Incorporation of such external informa-
tion can allow one to perform tests of association between untyped variants and phenotype, thereby making more efﬁcient use of the
available genotype data. When related individuals are included in case-control samples, the dependence among their genotypes must be
properly addressed for valid association testing. In the context of testing untyped variants, an additional analytical challenge is that the
dependence, across related individuals, of the partial information on untyped-SNP genotypes must also be assessed and incorporated
into the analysis for valid inference.We address this challenge with ATRIUM, amethod for case-control association testing with untyped
SNPs, based on genome screen data in samples in which some individuals are related. ATRIUM uses LD information from an external
reference panel to specify a one-degree-of-freedom test of association with an untyped SNP. It properly accounts for dependence in
the partial information on untyped-SNP genotypes across related individuals. We demonstrate that ATRIUM is robust in that it main-
tains the nominal type I error rate even when the external reference panel is not well matched to the case-control sample. We apply
the method to detect association between type 2 diabetes and variants on chromosome 10 in the Framingham SHARe data.Introduction
With the rapid advances in high-throughput genotyping
technology, genome-wide association studies have become
a viable approach to elucidating the genetic basis of
human complex disease. It is now affordable to analyze
on the order of 105 to 106markers throughout the genome.
However, because the set of single-nucleotide polymor-
phisms (SNPs) assayed by the current genotyping plat-
forms covers only a fraction of the total variation in the
human genome, it is likely that many disease-suscepti-
bility alleles are not directly genotyped. Therefore, it is of
great interest to develop powerful statistical methods to
detect association with untyped causal variants. To do
this, one can use the linkage disequilibrium (LD) structure
of the genome, together with data on typed variants,
to detect association between untyped variants and
phenotype.
In the context of unrelated individuals, several
approaches have been developed, including imputation
approaches,1–8 a likelihood-based method,9 testing of tag
SNPs,10 and testing of haplotypes of tag SNPs,11 as well
as TUNA12,13 and related approaches14 that contrast esti-
mated allele frequencies for cases and controls, where the
estimates are based on a linear combination of haplotype
frequencies of tag SNPs. A recent extension of BEAGLE8
allows imputation of genotypes for parent-offspring pairs
and trios as well as for unrelated individuals. This is an
improvement over the approach of applying, to related
individuals, imputation methods that were designed for
unrelated individuals, because it allows one to use addi-The Americantional phase information from relatives and it avoids the
introduction of Mendelian errors.
A key concern for case-control association testing with
related individuals is that imputed genotypes are depen-
dent among relatives, where the dependence among
imputed genotypes differs from the ordinary dependence
among genotypes and is affected by the type and amount
of information available for each individual. This complex
dependence among imputed genotypes would need to be
taken into account in the analysis in order to construct
a valid test. However, to our knowledge, the current gener-
ation of imputation methods gives information only on
the marginal accuracy (e.g., marginal posterior probabili-
ties and not joint posterior probabilities) of imputed geno-
types, so these methods would not allow valid assessment
of uncertainty in the general setting of case-control associ-
ation testing with related individuals.
A few methods of case-control association testing that
allow arbitrary combinations of related and unrelated
individuals have been developed, including methods to
detect association with a typed marker15–17 and methods
to detect haplotype association.18–20 In this article, we
propose the Association Test with Related Individuals for
Untyped Markers, or ATRIUM. ATRIUM is a one-degree-
of-freedom (1-df) association test based on genotype data
from multiple typed SNPs that are in LD with the untyped
SNP, where information on the joint distribution of typed
and untyped SNPs is obtained from an external reference
panel, andwhere the sample can include familymembers as
well as unrelated individuals. ATRIUM properly accounts
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SNPgenotypes across related individuals. Becausewecondi-
tion the analysis on the external LD information, ATRIUM
still properly controls type I error even when the reference
panel is not well matched to the case-control sample.
Through simulation studies, we also investigate issues
that may affect the power of ATRIUM, including limited
size of the reference panel andmismatch between the refer-
ence panel and the case-control sample. We compare the
power of ATRIUM with that of some existing approaches
for testing in this context. We apply the new method to
test for association of untyped SNPs with type 2 diabetes
(MIM 125853) in the Framingham SHARe data set.
Material and Methods
Suppose aparticular untypedgenetic variant,U, plays an important
role in the disease or binary trait of interest, and suppose that this
leads to an association between U and case-control status. The
idea behind ATRIUM is that, if we consider an appropriate set of
typed markers,M ¼ ðM1,.,Mt Þ, known to be in strong LD with
U based on external information, then the primary association of
U with case-control status will induce a secondary association of
haplotypes of M with case-control status. Rather than applying
a generic test of association between haplotypes of M and case-
control status, we can improve power to detect association attribut-
able to the untyped variant U by using the information, available
from an external reference such as HapMap, on the joint distribu-
tion of alleles of U and haplotypes of M, to construct a 1-df test
that has power in the direction that corresponds to association of
U with the trait. By ‘‘has power in the direction that corresponds
to association of U with the trait,’’ we mean that we test for the
speciﬁc pattern of change in frequencies of haplotypes of M
between cases and controls thatwouldbe expected if thehaplotype
frequency changewere driven by association between the trait and
U. Themajormethodological challenges indevelopingATRIUMare
due to (1) allowing samples that contain related individuals and (2)
the fact that genotypes, not haplotypes, are observed. The haplo-
type information used by ATRIUM for each sampled individual is
based on the individual’s own genotypes as well as genotype infor-
mationon the individual’s parentswhenavailable. Theuncertainty
in haplotype information and the dependence of haplotype infor-
mation across related individuals are directly taken into account in
the analysis through the use of the IQLS method.20 The result is
a test of association with an untyped SNP, based on genotype
data on associated markers M with missing data allowed, where
the test is applicable in samples that contain related individuals,
assuming that the individuals are outbred and that pedigree infor-
mation is available.
We ﬁrst brieﬂy outline the method; more detailed development
is given in the following paragraphs. To construct the ATRIUM
test, we start with the MQLS association model,17 which was
developed for testing case-control association with a typed SNP
in samples that contain related individuals. The MQLS model for
the association of the untyped SNP U with the trait implies amodel
for association of the haplotypes ofMwith the trait. This allows us
to form a 1-df, complete-data, quasi-likelihood score test for case-
control association with the untyped SNP in related individuals,
based on haplotype data fromM. To extend the test to the more
realistic situation in which genotype, not haplotype, information
is available,we use the IQLS framework,20whichprovides a general668 The American Journal of Human Genetics 85, 667–678, Novembapproach to quasi-likelihood inference in the presence of both
dependent and missing data. Application of the IQLS framework
allows us to test for case-control association with U by forming
the 1-df, incomplete-data, ATRIUM test based on genotype data
on associated markersM in related individuals.
Mean Model for Untyped SNP
Suppose we have a case-control sample of n outbred individuals,
some of whom may be related with relationships speciﬁed by
knownpedigrees.We arbitrarily label the two alleles of the untyped
SNP U as ‘‘0’’ and ‘‘1,’’ and we let U be the unobserved vector of
genotypes at U, where we deﬁne U ¼ (U1, ., Un)T by Ui ¼
1=23ðthe number of copies of allele 1 at U held by individual iÞ,
1 % i % n. We let A be the observed phenotype vector, where
we deﬁne A ¼ (A1, ., An)T by Ai ¼ 1 if individual i is affected,
– K/(1 – K) if i is unaffected, and 0 if i’s phenotype is unknown.
Here 0 < K < 1 is a constant that represents an external estimate
of the population prevalence of the trait. (The prevalence estimate
is permitted to be very rough; the MQLS test is, in fact, valid for
arbitrary ﬁxed K.) The MQLS model speciﬁes that
EðUi jAÞ ¼ pþ gðFAÞi¼ pþ g
Xn
j¼1
2fijAj: (Equation 1)
Here p represents the population frequency of allele 1 at U, which
is treated as an unknown nuisance parameter; fij represents the
kinship coefﬁcient between individuals i and j, which is assumed
known; F is the n 3 n kinship matrix having (i, j)th element
2fij; and g is the unknown parameter of interest representing
the strength and direction of association between the phenotype
and the alleles of U. This model incorporates the enrichment
effect, which speciﬁes, for example, that affected individuals
with affected relatives are more likely to have alleles predisposing
to the trait than are affected individuals without affected relatives.
The MQLS score test based on this model was previously shown17
to have high power to detect case-control association with a typed
SNP, for a variety of multilocus trait models, in samples containing
related individuals.
Mean Model for Haplotypes at Typed Markers in LD
with Untyped SNP
For the untyped SNP U, a set of typed SNPsM is chosen based on
somemultilocus measure of association,14,21–23 so that haplotypes
ofM are highly informative about alleles of U. Suppose there are
H þ 1 possible haplotypes of M, where for 1 % j % H þ 1; we
assume 0< hj< 1 is the population frequency of the jth haplotype,
with
PHþ1
j¼1 hj ¼ 1. The haplotype frequency vector h ¼ (h1, .,
hH)
T is treated as an unknown nuisance parameter in the analysis.
We let Y ¼ (Y11, ., Y1H, ., Yn1, ., YnH)T, where Yij ¼
1=23ðthe number of copies of haplotype j held by individual iÞ,
1 % i % n, 1 % j % H þ 1. If we assume that any association
between haplotypes ofM and the trait is a secondary association
that is attributable to the direct effect of U on the trait, then we
can derive a mean model for haplotypes ofM based on Equation
1. More precisely, we assume that given the allele at U on a partic-
ular chromosome, the haplotype at M on that chromosome is
conditionally independent of the phenotype information. Then
we ﬁnd (Appendix A) that
E

Yij jA
 ¼ hj þ g hjp1 j j  p
pð1 pÞ ðFAÞi, (Equation 2)er 13, 2009
where p1jj is deﬁned to be the conditional probability that a chro-
mosome has allele 1 at U given that it has the jth haplotype atM.
Thus, the association effect for the jth haplotype is ghj(p1jj – p)/
[p(1 – p)], where g is the association effect for allele 1 of U, and
hj(p1jj – p)/[p(1 – p)] is the slope of the regression line for the simple
linear regression of the haplotype indicator Yj ¼ (Y1j, ., Ynj)T on
the allele indicator U. If we reparameterize the model in terms of
a new association parameter r ¼ g/[p(1 – p)] and apply the identity
p ¼PHþ1k¼1 hkp1jk, then we obtain the equivalent mean model
E

Yij jA
 ¼ hj þ rhjp1 j j XHþ1
k¼1
hkp1 j k

ðFAÞi: (Equation 3)
The genotype data for the case-control sample give direct informa-
tion on h but give no information at all on the p1jj’s. Therefore we
replace each p1jj by an estimate, bpR1jj, which is obtained from
the reference panel and is taken to be
bpR1 j j ¼bhRj,1bhRj , (Equation 4)
provided bhRj > 0, where bhRj denotes an estimate of haplotype
frequency hj in the reference panel, andbhRj,1 denotes an estimate,
from the reference panel, of the frequency of the haplotype
having allele 1 at U and haplotype j atM. Then we deﬁne hj by
hj ¼ hj
bpR1 j j XHþ1
k¼1
hkbpR1 j k, (Equation 5)
which can be treated in the analysis as a ﬁxed function of
the unknown haplotype frequency h. (When bhRj ¼ 0, we setbpR1jj ¼ ðPHþ1k¼1 hkbpR1jk1bhRk>0Þ=ðPHþ1l¼1 hl1bhRl >0Þ, which, when plugged
into Equation (5), leads to hj ¼ 0.) Combining Equations 5 and
3, we ﬁnally obtain
E

Yij jA
 ¼ hj þ hj rðFAÞi, (Equation 6)
which is the mean model for haplotypes ofM, based on the infor-
mation, from the reference panel, on LD between alleles of U and
haplotypes of M. Alternatively, we could use a logistic version
(Appendix B) of the model in Equation 6, and we would still
obtain the same quasi-likelihood score test as in the next subsec-
tion. We note that the role of the reference panel information is
solely to determine the direction in which to perform a 1-df test,
so the accuracy of the reference panel information will affect
only the power, not the validity, of the score tests we propose in
the next two subsections.
ATRIUM When Haplotypes Are Observed
When the haplotypes atM are observed, ATRIUM is a 1-df, quasi-
likelihood score test based on the mean model in Equation 6.
Our null hypothesis is H0:r ¼ 0, and our alternative hypothesis is
HA:rs 0. The null hypothesis represents no association of haplo-
types of M with the trait, whereas the alternative hypothesis is
formulated to detect the speciﬁc kind of association that would
be expected if the haplotype association were driven by the effects
of the untyped SNP U.
To form ATRIUM in the case of observed haplotypes, we require
thenull conditional covariancematrixofY,whichcanbewrittenas
Var0ðY jAÞ ¼ Var0ðYÞ ¼ F5B, (Equation 7)
where B is the H 3 H matrix having (j, k)th element Bjk ¼
hj(1 – hj)/2 if j ¼ k and – hjhk/2 if j s k. We can also think of BThe Americaas being the correlation matrix of the H vector (Yi1, ., YiH) for
any individual i. Similarly, note that F (deﬁned in the previous
subsection) is the correlation matrix of the n vector Yj ¼ (Y1j, .,
Ynj)
T for any haplotype j. The Kronecker product 5 is deﬁned in
Appendix C. ATRIUM for the case when haplotypes are observed
is the quasi-likelihood score test based on the model of Equations
6 and 7, with the resulting ATRIUM test statistic given by
T¼
2
hPn
i¼1 Ai
PHþ1
j¼1 bpR1 j jðYij bhjÞi2h
ATFAAT12=1TF11ihPHþ1k¼1 bhkbpR1 j k2PHþ1l¼1 bhlbpR1 j l2i ,
(Equation 8)
where 1 is a vector with every entry equal to 1, andbhj ¼ ð1TF11Þ11TF1Yj is the BLUE24 of hj under the null
hypothesis of no association. In the special case when the individ-
uals are unrelated, the term [ATFA – (AT1)2/(1TF11)] in the
denominator reduces to
Pn
i¼1ðAi  AÞ2, where A ¼ n1
Pn
i¼1 Ai is
the sample average ofA. Under regularity conditions, the ATRIUM
test statistic T is asymptotically c21 distributed under the null
hypothesis of no association. This asymptotic null distribution
holds regardless of whether the reference panel provides biased
estimates of the p1jj, as might happen, for instance, when the refer-
ence panel and case-control sample are drawn from different pop-
ulations. Thus, validity of our test does not depend on choice of
reference panel.
While accuracy ofbpR1jj does not affect validity of the test, it can
affect power. WhenbpR1jj is exactly equal to the true p1jj, which one
could think of as the case of an inﬁnitely large, perfectly matched
reference panel, there is an optimality result for our test, namely,
that it is asymptotically locally most powerful among tests based
on Y (under regularity conditions and assuming that Equations 3
and 7 hold). Thus, compared to other association tests between
haplotypes of M and the trait, ATRIUM should have increased
power to detect case-control association with the untyped SNP U.
ATRIUM When Unphased Genotypes Are Observed
For the ith sampled individual, 1 % i % n, let Gi denote the
observed, unphased genotype data on the associated markersM,
where missing genotypes are allowed, and let G ¼ (G1, ., Gn).
Note that G provides only partial information about the haplo-
type indicator vector Y. To obtain the ATRIUM test statistic in
this setting, we use the IQLS method,20 which provides a quasi-
likelihood score test that can be used with missing and dependent
data. Instead of being based on Y, which is now only partially
observed, ATRIUM is the quasi-likelihood score test based
on a vector, Z, of conditional expectations of elements of Y,
which incorporates partial haplotype information. We deﬁne
Z ¼ (Z11,., Z1H,., Zn1,., ZnH)Twith Zij ¼ E(YijjGi, Gmi, Gﬁ, A),
where Gmi and Gﬁ denote the observed, unphased genotype data
for the mother and father of individual i, respectively, where these
may be missing. Throughout the analysis, we condition on the
observed pattern of missing genotypes, and we assume that the
pattern of missingness is not informative about the underlying
haplotypes.
We have E(ZjA) ¼ E(YjA), so the mean model of Equation 6 still
applies to Z. As before, we are interested in testing the null
hypothesis of no association between the trait and the untyped
SNP U, H0:r ¼ 0 versus HA:r s 0. Note that explicit computation
of Z under the alternative hypothesis would require additional
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method allows one to perform the quasi-likelihood score test
without having to actually compute Z under the alternative
model. We deﬁne U ¼ Var0(ZjA) ¼ Var0(Z) to be the conditional
covariance matrix of Z under the null hypothesis, and we let
Fr ¼ E0ðvðZ mÞ=vrjAÞ and Fh ¼ E0ðvðZ mÞ=vhjAÞ, where
m ¼ EðZjAÞ with mij given by Equation 6 and where E0($) denotes
expectation under the null hypothesis. Additional details on
how U, Fr, and Fh are obtained can be found in Appendix D.
Then the ATRIUM test statistic has the form
T ¼
( 
FTr U
1ðZ mÞ2
FTr U
1Fr  FTr U1Fh

FThU
1Fh
1
FThU
1Fr
)
ðr,hÞ¼ð0,bhÞ,
(Equation 9)
where the entire right-hand side is evaluated at ðr,hÞ ¼ ð0,bhÞ.
Here bh is the IQL estimator of h when r ¼ 0, which is the
solution to the IQLS equation FThU
1ðZ mÞ ¼ 0, when r ¼ 0.
This equation is easily solved numerically by an iterative algo-
rithm. The ATRIUM test statistic asymptotically follows a c21
distribution under the null hypothesis of no association, under
regularity conditions.20
Connections with Previous Methods for Unrelated
Individuals
The WHAP method14 has been developed for the special case of
complete haplotype information on the set of markers M in a
sample consisting of equal numbers of unrelated cases and
controls, where no distinction is made between unaffected
controls and unphenotyped (i.e., general population) controls.
The optimal-weight WHAP test statistic is obtained as a special
case of our complete-data ATRIUM test statistic in Equation 8,
under the assumptions that the sampled individuals are unrelated
and that the controls are all of one type, either all unaffected or all
unphenotyped.
The TUNAmethod12,13 uses a similar idea to test for association
with an untyped SNP in a sample of unrelated cases and controls,
when unphased genotype data are available on the set of markers
M. Where ATRIUM uses a score test, the TUNA software13 uses
a Wald test based on different null and alternative hypotheses
than those of ATRIUM. Nonetheless, in the special case of
complete haplotype data on unrelated individuals, where all
controls are of the same type, the TUNA and ATRIUM test statistics
are identical except for the choice of variance estimator.
Comparison to Other Approaches for Related
Individuals
In the next section, we perform simulation studies to compare the
power of ATRIUM to that of (1) the single-SNP MQLS association
test17 with the SNP among M1,.,Mt that has highest r
2 with
the untyped SNP; (2) the full-degree-of-freedom IQLS haplotype
association test20 applied to haplotypes ofM; and (3) a 1-df haplo-
type association test for deviation in the direction of the single
haplotype ofM that has highest r2 with the untyped SNP, where
test (3) is novel, to our knowledge. We now give a brief overview
of tests (2) and (3).
The full-degree-of-freedom IQLS haplotype association test20 is
similar to ATRIUM in that it is a quasi-likelihood score test based
on the vector Z, but it uses a different mean model given by
E

ZijjA
 ¼ EYijjA ¼ hj þ gjðFAÞi, (Equation 10)670 The American Journal of Human Genetics 85, 667–678, Novemwhere g ¼ ðg1,.,gHÞT is the parameter of interest, which
measures trait-haplotype association. The full-degree-of-freedom
IQLS test allows one to test H0 : g ¼ 0 versus HA : gs0. Under
regularity conditions, the asymptotic null distribution of the
IQLS test is c2H.
In addition, we propose a 1-df haplotype association test that, to
our knowledge, is novel. Let a denote the haplotype ofM that has
highest r2 with the untyped SNP. We modify the model of Equa-
tion 10 to incorporate the constraint gj ¼ gahj=ð
PHþ1
k¼1,ksa hkÞ,
for j s a. The resulting model has a one-dimensional parameter
of interest, ga, which represents association between the trait
and haplotype a. The constraint speciﬁes that conditional on
a haplotype being not of type a, its type is independent of the
phenotype information. Then we perform the quasi-likelihood
score test of the null hypothesisH0:ga¼ 0 versusHA:gas 0, which
is a test of association between the trait and haplotype a. This test
is equivalent to the ATRIUM test with the setting bpR1ja ¼ 1, andbpR1jj ¼ 0, for j s a. In other words, we are effectively assuming
that the untyped SNP is in perfect LD with haplotype a.
Results
Simulation Studies
We perform simulation studies to explore the validity and
power of ATRIUM. We consider a scenario in which a
case-control sample is genotyped for the Illumina 300K
SNP set. The European (CEU) HapMap sample is taken to
be a well-matched reference panel for the population
from which the case-control sample is drawn. (Note that
although we use the CEU HapMap sample to choose tag
SNPs, we actually simulate a reference panel for each repli-
cate of our simulation studies, with the simulated reference
panel used for calculation of bpR1jj.) We refer to any SNP
in HapMap that is not in the Illumina 300K set as an
‘‘untyped’’ SNP. For each untyped SNP on chromosome 1,
we use the TUNA software to ﬁnd a set of four Illumina
300K tag SNPs that maximizes the MD information
measure23 within a 400 kb window, based on the 60
HapMap CEU parents’ data. (MD can be viewed as a multi-
locus extension of r2. It can be interpreted as the asymp-
totic ratio of sample sizes needed to obtain the same power
when the SNP is typed versus when it is untyped and
a particular set of tag SNPs is used.23) From each set of
four tag SNPs, we then remove SNPs that do not provide
signiﬁcant information on the untyped SNP, based on
the adjusted MD measure.
13 We randomly choose ﬁve of
the untyped SNPs on chromosome 1, from among those
with MD R 0.4, to be used in the simulations. Tables 1–5
list the joint distributions, estimated from the CEU
HapMap sample, for each of these ﬁve untyped SNPs
with their Illumina 300K tag SNPs. In the simulations,
we assume that the distributions in Tables 1–5 represent
the true joint distributions, of the corresponding SNP
sets, in the population fromwhich the case-control sample
is drawn.
We simulate the case-control data based on a trait model
with two unlinked causal SNPs, both acting dominantly,
with epistasis between them. The minor allele frequenciesber 13, 2009
(MAFs) of SNP 1 and SNP 2 are denoted by p1 and p2,
respectively. In addition to the two allele frequencies, there
are two penetrance parameters, f1 and f2 (f1 > f2), with
penetrance f1 for individuals who have at least one copy
of the minor allele at SNP 1 and at least one copy of the
minor allele at SNP 2 and penetrance f2 for all other indi-
viduals. We consider ﬁve different parameter settings,
which are listed as Models a–e in Table 6. For each model,
we set SNP 2 to be one of the untyped SNPs in Tables 1–5,
and its MAF, p2, is determined accordingly. Table 6 gives
the trait model parameters; the resulting population prev-
alence, K; and the sibling risk ratio, ls ¼ Ks/K, where Ks is
the prevalence conditioned on having an affected sibling.
We sample 90 outbred, three-generation, 16-person pedi-
grees, of which 30 pedigrees have four affected individuals,
30 have ﬁve affected individuals, and 30 have six affected
individuals. In each sampled pedigree, phenotypes for all
16 individuals are observed. The individual’s genotypes
are observed if and only if at least 30% of the individual’s
siblings, parents, and offspring are affected. This is similar
to the study design in a previous report.17
An important feature of the ATRIUM analysis is that it is
conditional on the value of bpR1jj obtained from the refer-
ence panel. This results in a theoretical robustness property
for type I error of the test, namely, ATRIUMwill be valid, in
the sense of having the correct type I error, even whenbpR1jj
is a biased or inaccurate estimate of p1jj. We verify this in
our simulations, and we also use simulations to assess the
impact of the reference panel on power. Speciﬁcally, we
Table 1. Haplotype Frequencies, Estimated from the CEU HapMap
Sample, for SNP rs10797373, denoted by U, and Three Tag SNPs on
the Illumina 300K Set
Haplotype M1 M2 M3 U Frequency
H1 0 0 1 1 0.158
H2 0 1 1 1 0.042
H3 1 0 0 1 0.092
H4 1 0 1 0 0.075
H5 1 1 0 1 0.067
H6 1 1 1 0 0.567
Table 2. Haplotype Frequencies, Estimated from the CEU HapMap
Sample, for SNP rs10907174, Denoted by U, and Three Tag SNPs on
the Illumina 300K Set
Haplotype M1 M2 M3 U Frequency
H1 0 0 1 0 0.017
H2 0 1 0 0 0.708
H3 1 0 1 1 0.083
H4 1 1 0 0 0.017
H5 1 1 0 1 0.125
H6 1 1 1 0 0.033
H7 1 1 1 1 0.017The Americanconsider the effect on power of (1) bias inbpR1jj introduced
by a mismatched reference panel and (2) variability inbpR1jj
because of small sample size of the reference panel. To
assess (1), we compare results from simulations based on
three different types of reference panel: well-matched, in
which the reference panel consists of phased genotype
data on 60 unrelated individuals simulated based on the
CEU HapMap sample; mismatched, in which the reference
panel consists of phased genotype data on 90 unrelated
individuals simulated based on the Asian (JPTþCHB)
HapMap sample; and extremely mismatched, in which
the reference panel consists of phased genotype data on
60 unrelated individuals simulated based on the African
(YRI) HapMap sample. To assess (2), we compare results
from simulations in which the true value of p1jj is plugged
in for bpR1jj (‘‘perfect panel’’) to those in which bpR1jj is
estimated from the well-matched reference panel of 60
unrelated individuals described above. In our simulations,
every replicate of the case-control sample has its own simu-
lated reference panel (except ‘‘perfect panel’’ in which true
values are used instead of a reference panel).
For the assessment of type I error, association is tested
with an untyped SNP that is unlinked and unassociated
Table 3. Haplotype Frequencies, Estimated from the CEU HapMap
Sample, for SNP rs2794347, Denoted by U, and Three Tag SNPs on
the Illumina 300K Set
Haplotype M1 M2 M3 U Frequency
H1 0 0 0 0 0.050
H2 0 0 0 1 0.008
H3 0 1 0 0 0.675
H4 0 1 0 1 0.067
H5 0 1 1 0 0.017
H6 0 1 1 1 0.042
H7 1 0 0 0 0.008
H8 1 0 0 1 0.075
H9 1 1 0 0 0.050
H10 1 1 0 1 0.008
Table 4. Haplotype Frequencies, Estimated from the CEU HapMap
Sample, for SNP rs12031614, Denoted by U, and Three Tag SNPs on
the Illumina 300K Set
Haplotype M1 M2 M3 U Frequency
H1 0 0 0 1 0.025
H2 0 0 1 1 0.208
H3 0 1 0 0 0.108
H4 0 1 0 1 0.133
H5 1 0 0 0 0.008
H6 1 0 0 1 0.033
H7 1 0 1 0 0.050
H8 1 1 0 0 0.433Journal of Human Genetics 85, 667–678, November 13, 2009 671
with any causal variant, where phenotype is simulated
according toModel b. We compare the proportion of simu-
lations in which the statistic exceeds the (1 – a)th quantile
of the c1
2 distribution to the nominal type I error level a,
for a ¼ 0.01 and 0.05. Table 7 gives the empirical type I
error of the ATRIUM test, based on 10,000 replicates,
wherebpR1jj is obtained from a reference panel that mimics
the HapMap CEU, YRI, or JPTþCHB sample. We ﬁnd that
even for an extremely mismatched (YRI) reference panel,
type I error is not signiﬁcantly different from the nominal
level when a ¼ 0.05 or 0.01. These results verify that the
type I error of the ATRIUM test for an untyped SNP is
robust to the choice of reference sample.
To assess power for each model, we mask the genotypes
at causal SNPs 1 and 2 and perform the tests based only on
the tag SNPs for SNP 2, which are given in Tables 1–5 for
Models a–e, respectively. These tag SNPs form the set M
described in Material and Methods. Table 7 illustrates the
power of ATRIUM for the three different types of reference
panel. Under Models a, b, and e, power remains high even
when the mismatched JPTþCHB reference panel is used,
and power is reasonable even for the extremely mis-
matched YRI reference panel. However, in Models c and d,
power is compromised with a mismatched reference panel.
This results from the fact that the joint haplotype distribu-
tion of SNP 2 with its tag SNPs differs dramatically across
Table 5. Haplotype Frequencies, Estimated from the CEU HapMap
Sample, for SNP rs10910097, Denoted by U, and Four Tag SNPs on
the Illumina 300K Set
Haplotype M1 M2 M3 M4 U Frequency
H1 0 0 0 0 0 0.025
H2 0 0 0 0 1 0.050
H3 0 0 0 1 1 0.050
H4 0 0 1 0 0 0.250
H5 0 0 1 1 0 0.075
H6 0 1 0 0 0 0.067
H7 0 1 0 1 0 0.383
H8 1 0 0 0 1 0.083
H9 1 1 0 0 1 0.017
Table 6. Parameter Settings for Simulation Models
Minor Allele
Frequencies
Penetrance
Parameters
Model SNP 2 p1 p2 f1 f2 K ls
a rs10797373 0.15 0.358 0.15 0.05 0.066 1.118
b rs10907174 0.30 0.225 0.22 0.09 0.116 1.075
c rs2794347 0.40 0.200 0.40 0.20 0.246 1.045
d rs12031614 0.50 0.400 0.18 0.07 0.123 1.077
e rs10910097 0.35 0.200 0.25 0.10 0.131 1.081672 The American Journal of Human Genetics 85, 667–678, Novembthe three populations (where this distribution for the
CEU sample is given in Tables 3 and 4).
Table 8 compares the power of ATRIUM, with a well-
matched reference panel of 60 unrelated individuals, to
the power of three other tests that are valid in samples
containing related individuals: (1) the single-SNP MQLS
association test with the SNP in M that has the highest
r2 with the untyped SNP; (2) the full-degree-of-freedom
haplotype test applied to the haplotypes of M; and (3)
the 1-df haplotype association test for deviation in the
direction of the single haplotype ofM that has the highest
r2 with the untyped SNP. In every setting, the ATRIUM test
outperforms the other three, verifying that in samples con-
taining related individuals, the strategy of using reference
panel information to select an optimal direction for testing
association with an untyped SNP improves power over
other approaches. To assess the possible effects on power
of variability inbpR1jj as a result of small sample size of the
reference panel, we also compare the power of ATRIUM
with the well-matched reference panel of 60 unrelated
individuals to ATRIUM with the true value of p1jj plugged
in for bpR1jj (‘‘perfect panel’’). Based on these simulations,
there appears to be little loss of power between the unat-
tainable perfect panel and the well-matched reference
panel.
Analysis of Type 2 Diabetes in the Framingham SHARe
Data
The Framingham Heart Study (FHS)25 is a multicohort,
longitudinal study of risk factors for cardiovascular disease.
The FHS sample consists of unrelated individuals as well
as individuals from multigenerational pedigrees. For indi-
viduals in Cohort 1 (original Framingham cohort), we
use the data from exams 1–27 to determine type 2 diabetes
status, which is coded as follows: individuals with at least
one exam with (nonfasting) blood glucose (BG) level R
200 mg/dl or who were under treatment for diabetes,
where the measurement or treatment occurred between
the ages of 35 and 75 years, are classiﬁed as affected. We
classify as unaffected those who satisfy all of the following
conditions: (1)R 70 years at the time of the last exam for
which BG is available, (2) BG < 200 mg/dl for all exams
for which it is available, and (3) not taking any treatment
by the time of the last exam. We classify as unknown
phenotype those who were < 70 years at the time of
the last exam for which BG is available and who satisfy
both conditions (2) and (3). For individuals in Cohort 2
(offspring cohort), we use the data from exams 1–7, and
for individuals in Cohort 3 (generation three cohort), we
use the data from exam 1 to determine type 2 diabetes
status, which is coded as follows for Cohorts 2 and 3: indi-
viduals with at least one exam with fasting plasma glucose
(FPG) R 126 mg/dl or who were under treatment for
diabetes, where the measurement or treatment occurred
between the ages of 35 and 75 years, are classiﬁed as
affected. We classify as unaffected those who satisfy all of
the following conditions: (1)R 70 years at the time of theer 13, 2009
Table 7. Power and Type I Error of ATRIUM, When the Reference Panel Is Well Matched to the Sample or Mismatched, Based on 5,000
Simulated Replicates for Power or 10,000 Simulated Replicates for Type I Error
Empirical Type I Error (SE) Estimated Power (SE) with Significance Level of 0.05
Reference Panel a ¼ 0.05 a ¼ 0.01 Model a Model b Model c Model d Model e
CEU (match) 0.050 (0.002) 0.009 (0.0010) 0.915 (0.004) 0.957 (0.003) 0.868 (0.005) 0.859 (0.005) 0.985 (0.002)
JPTþCHB (mismatch) 0.049 (0.002) 0.011 (0.0010) 0.911 (0.004) 0.944 (0.003) 0.447 (0.007) 0.782 (0.006) 0.932 (0.004)
YRI (extreme mismatch) 0.051 (0.002) 0.010 (0.0010) 0.838 (0.005) 0.750 (0.006) 0.355 (0.007) 0.432 (0.007) 0.930 (0.004)last exam for which FPG is available, (2) FPG < 126 mg/dl
for all exams for which it is available, and (3) not taking
any treatment by the time of the last exam. We classify
as unknown phenotype those who were < 70 years at the
time of the last exam for which FPG is available and who
satisfy both conditions (2) and (3). Note that for exams
1 and 2 for Cohort 2, instead of the FPG R 126 mg/dl
criterion, we use the hand-curated diabetes mellitus (DM)
status, which is based on detailed chart review and is avail-
able for exams 1 and 2 of Cohort 2 in Framingham SHARe.
This study had approval from dbGaP and from the Univer-
sity of Chicago Institutional Review Board.
Among the FHS individuals who are genotyped on the
Affymetrix 500K array, and who are coded as affected,
unaffected, or unknown phenotype based on the above
criteria, we include only those who satisfy the following
quality-control conditions: (1) completeness> 96%, where
completeness is the proportion of all markers on the
Affymetrix 500K array for which a given individual has
genotypes called, and (2) diagonal of empirical kinship
matrix<1.05.Wealsouse theoff-diagonals of the empirical
kinship matrix to exclude an additional 298 individuals
with kinship values that are not consistent with the pedi-
gree information. Based on the above criteria, a total of
7,678 individuals are retained in the analysis, with 576
affected, 1,254unaffected, and5,848unknownphenotype,
ofwhich793 are original cohort, 3,142 are offspring cohort,
and 3,743 are third generation.
We perform case-control association testing of type 2
diabetes with both typed and untyped SNPs on chromo-
some 10 in the Framingham SHARe data. The typed SNPs
in the analysis consist of the 21,777 SNPs on chromosome
10 that are on the Affymetrix 500K array, pass the Affyme-The Americantrix 500K quality-control tests, and meet the following
additional criteria: (1) call rateR 96%, (2) Mendelian error
rate % 0.02, and (3) MAF R 0.01. The untyped SNPs in
the analysis are the 60,344 SNPs on chromosome 10 in
HapMap that meet the following criteria: (1) are not
among the 21,777 typed SNPs and (2) are tagged by at least
two typed SNPs, where the tagging is done by applying
TUNA to the CEU HapMap samples, in a similar fashion
to what is described in detail in subsection Simulation
Studies (with the Illumina 300K array replaced by the Affy-
metrix 500K array and with chromosome 1 replaced by
chromosome 10). We use MQLS to test for association
with each typed SNP and ATRIUM to test for association
with each untyped SNP. The prevalence of diagnosed and
undiagnosed diabetes among people aged 60 years or older
in the United States is reported to be ~23%, with type 2 dia-
betes accounting for about 90%–95% of all diagnosed cases
of diabetes.26 Therefore, we set K ¼ 0.2 in the MQLS and
ATRIUM analyses.
Table 9 gives the results for SNPs for which the corre-
sponding ATRIUM or MQLS test has a p value < 8.0 3
105. The ﬁrst SNP in Table 9 (rs2904802) is in an intron
of the gene encoding aldo-keto reductase family 1,member
C1 (AKR1C1 [MIM 600449]), located at 10p15.1. The next
four SNPs in Table 9 (rs7901695, rs4506565, rs7903146,
and rs4132670) are intronic SNPs for the gene encoding
transcription factor 7-like 2 (TCF7L2 [MIM 602228]),
located at 10q25.2. Recently, ﬁve separate type 2 diabetes
genome-wide association studies27–31 have identiﬁed asso-
ciation between TCF7L2 and type 2 diabetes. One study32
has shown that the rs7903146 T allele is associated with
hepatic insulin resistance and diminished glucose-stimu-
lated plasma insulin secretion. The sixth SNP in Table 9Table 8. Power of ATRIUM Compared to Single-SNP and Haplotype Association Tests, Based on 5,000 Simulated Replicates, a ¼ 0.05, CEU
Reference Panel
Estimated Power (SE)
Test Model a Model b Model c Model d Model e
SNP 0.555 (0.007) 0.946 (0.003) 0.530 (0.007) 0.749 (0.006) 0.793 (0.006)
HAP (full degree of freedom) 0.723 (0.006) 0.856 (0.005) 0.713 (0.006) 0.650 (0.007) 0.899 (0.004)
HAP (1 degree of freedom) 0.849 (0.005) 0.935 (0.003) 0.723 (0.006) 0.832 (0.005) 0.741 (0.006)
ATRIUM 0.915 (0.004) 0.957 (0.003) 0.868 (0.005) 0.859 (0.005) 0.985 (0.002)
ATRIUM (perfect panel)a 0.915 (0.004) 0.960 (0.003) 0.887 (0.005) 0.867 (0.005) 0.987 (0.002)
a ATRIUM (perfect panel) is ATRIUM with true p1jj plugged in for bpR1jj.Journal of Human Genetics 85, 667–678, November 13, 2009 673
Table 9. Type 2 Diabetes Association Results in Framingham SHARe, for Typed and Untyped SNPs on Chromosome 10
Region Gene SNP Position (nucleotides) Typed # of Tag SNPs MD Test p Value
10p15.1 AKR1C1 rs2904802 4,999,364 no 4 0.44 ATRIUM 4.8e5
10q25.2 TCF7L2 rs7901695 114,744,078 yes – – MQLS 4.9e6
10q25.2 TCF7L2 rs4506565 114,746,031 yes – – MQLS 3.1e6
10q25.2 TCF7L2 rs7903146 114,748,339 no 3 0.94 ATRIUM 1.9e5
10q25.2 TCF7L2 rs4132670 114,757,761 yes – – MQLS 2.4e5
10q26.13 GPR26a rs859510 125,337,377 no 4 1.00 ATRIUM 7.8e5
10q26.2 DOCK1 rs4615933 128,716,002 no 4 0.65 ATRIUM 3.4e5
10q26.2 DOCK1 rs6482989 128,753,959 no 3 0.68 ATRIUM 1.6e5
10q26.2 DOCK1 rs9418739 128,758,976 yes – – MQLS 3.4e5
a rs859510 is 78.5 kb upstream of the gene GPR26.(rs859510) is 78.5 kb from the gene encoding G protein-
coupled receptor 26 (GPR26 [MIM 604847]), located at
10q26.13. This SNP lies in a previously identiﬁed,33 6.3 Mb
linkage region, for hemoglobin AIc (HbA1c), a diabetes-
related quantitative glucose trait, in the FHS based on the
Affymetrix 100K array. The last three SNPs in Table 9
(rs4615933, rs6482989, and rs9418739) are intronic SNPs
for the gene encoding dedicator of cytokinesis 1 (DOCK1
[MIM 601403]), located at 10q26.2.
Previous studies have found the region 10q25-q26 to be
syntenic to several quantitative trait loci for both weight
and type 2 diabetes in rats.34–36 10q25-q26 also contains
a 6.3 Mb region showing evidence for linkage to HbA1c
in FHS.33 Figure 1 shows our FHS type 2 diabetes associa-
tion results for the 10q25-q26 region, where we plot –log
10(p value) for each of 12,653 untyped HapMap SNPs,
based on ATRIUM, and 4,550 typed Affymetrix 500K674 The American Journal of Human Genetics 85, 667–678, NovemSNPs, based on MQLS. Overall, the untyped SNPs are
well represented among those SNPs having small p values,
taking into account the fact that although they represent
about 75% of the tested SNPs, the tests for untyped
SNPs are generally expected to have lower power because
of lower information content. In the previously identiﬁed
linkage region (119.5–125.8 Mb), the untyped SNPs pro-
vide stronger evidence of association than do the typed
SNPs.
Assessment of Computation Time
The computational burden of untyped SNP analysis is
much greater in samples containing related individuals
than it is in samples of unrelated individuals. This is
because the dependence, across related individuals, of
the partial information on untyped-SNP genotypes must
be assessed and incorporated into the analysis. We note110 115 120 125 130 135
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Figure 1. Association Results for Type 2 Diabetes in Framingham SHARe for the Region 10q25-q26
–log10(p value) is plotted against chromosomal location for 4,550 typed SNPs (blue circles) and 12,653 untyped SNPs (red x).ber 13, 2009
that this dependence differs from the ordinary dependence
among genotypes and is affected by the type and amount
of information available, on the untyped-SNP genotype,
for each individual. Thus, the computationally costly
part of ATRIUM is the calculation, at each iteration, of
the covariance matrix U.
The Framingham SHARe data we analyze contain some
extremely large pedigrees. For instance, there is one family
with 317 genotyped individuals who are included in our
analysis, and there are four other families that each have
more than 90 genotyped individuals included in our anal-
ysis. Accordingly, we did two different assessments of the
computation time needed to test the 60,344 untyped
SNPs of chromosome 10: (1) computation with extremely
large pedigrees, where we include 7,678 individuals from
1,147 families with the number of genotyped individuals
per family ranging from 1 to 317, with ﬁve families having
90 or more genotyped individuals; and (2) computation
withmoderate-size pedigrees, where we include 4,926 indi-
viduals from 1,084 families in which there are no more
than 20 genotyped individuals per family. With extremely
large pedigrees, the analysis took 17.5 hr on an Intel
2.6 GHz Mac laptop with 4 GB RAM when the haplotype
information for an individual is based only on that
individual’s genotype (i.e., when Zij is taken to be Zij ¼
E(YijjGi, A)), and it took 45 hr when we included parental
genotype data when considering an individual’s haplotype
information (i.e., when Zij is taken to be Zij ¼ E(YijjGi, Gmi,
Gﬁ, A)). With moderate-size pedigrees, it took 4.5 hr to do
the analysis when haplotype information for an individual
is based only on that individual’s genotype, and it took
12 hr to do the analysis when we included parental geno-
type data when considering an individual’s haplotype
information.We have not optimized the code, so it is likely
that these times could be greatly improved.
Discussion
We propose the ATRIUM method for testing association
with untyped genetic variants in samples containing
general combinations of related and unrelated individuals.
An important feature of ATRIUM is that it properly
accounts for dependence in the partial information on
untyped-SNP genotypes across related individuals, which
is crucial for construction of a valid test. ATRIUM is poten-
tially useful in a wide range of study designs, including
extremely large pedigrees as well as samples that combine
families and unrelated individuals. ATRIUM uses informa-
tion from an external reference panel, such as HapMap, to
select an optimal direction for testing association with
an untyped SNP, based on genotype data from typed
SNPs. ATRIUM allows both phased and unphased geno-
type data for both the case-control sample and the
reference panel. We demonstrate, both theoretically and
through simulation, that the validity of ATRIUM is robust
to mismatch between the reference panel and the case-
control sample, though power is highest when the refer-The Americanence panel is reasonably well-matched to the case-control
sample.We also ﬁnd that small sample size of the reference
panel results in little loss of power. We further demon-
strate, both theoretically and through simulation, that
ATRIUM provides higher power to detect association
with untyped SNPs than do other single-SNP and haplo-
type tests based on typed SNPs.
We apply ATRIUM to the Framingham SHARe data to test
for association between type 2 diabetes and SNPs on chro-
mosome 10 that are in HapMap but are untyped on the
Affymetrix 500K array in the Framingham sample. We
replicate association between type 2 diabetes and intronic
SNPs of the TCF7L2 gene, where we obtain p values for
association in the range of 3.1e6 to 2.4e5 for three typed
and one untyped intronic SNP of TCF7L2. We also obtain
p values < 8e5 for SNPs in or near three other genes on
chromosome 10, including one typed and two untyped
intronic SNPs for the DOCK1 gene. In a previously identi-
ﬁed linkage region for a diabetes-related phenotype,33 the
untyped SNPs, analyzed with ATRIUM, provide stronger
evidence for association than do the typed SNPs.
A key challenge that arises in association analysis with
samples of related individuals is that speciﬁcation of an
alternative model is vastly more problematic with related
than with unrelated individuals. This is because the back-
ground effects of environmental factors and multiple
loci, other than the particular variant being tested, can
create very different patterns of dependence of phenotype
among related individuals under different modeling
assumptions. This makes it particularly challenging to
develop appropriate likelihood-based or Bayesian analyses
in this context. The use of a score-function or quasi-score-
function approach, as in ATRIUM, avoids this problem. A
close connection between the MQLS and IQLS tests and
the retrospective likelihood score test has previously been
shown.20 A key point is that the retrospective likelihood
score, MQLS, IQLS, and ATRIUM tests can be formed
without specifying the joint distribution of phenotypes
among related individuals under the null or alternative
hypothesis, whereas likelihood-based and Bayesian
approaches would, in principle, require this to be speciﬁed.
Ideally, one should be able to improve the power of
ATRIUM by making use of one or more of the available
hidden Markov model (HMM) imputation approaches1–8
for the modeling and computation of the conditional
probabilitiesbpR1jj that are needed from the reference data-
base. A difﬁculty is that the calculation of the required
covariance matrix U becomes increasingly onerous as the
number of possible haplotypes of typed SNPs used to
predict the untyped SNP increases. An analogous problem
arises if imputation methods are used directly on the case-
control sample with related individuals, because it would
be necessary to compute and take into account the joint
posterior distribution, across related individuals, of the
untyped SNP genotypes. To our knowledge, current impu-
tation methods do not provide these joint posterior prob-
abilities for related individuals.Journal of Human Genetics 85, 667–678, November 13, 2009 675
When comparing p values across SNPs, particularly
when there are both typed and untyped SNPs being tested,
it is useful to keep in mind that the p value does not make
any adjustment for the differing power of the tests. This
is particularly relevant when typed and untyped SNP
p values are compared, because power to detect association
with an untyped SNP will be reduced to the extent that the
untyped SNP is not well characterized by haplotypes of
typed SNPs. The extent of information on the untyped
SNP, relative to the information that would be available if
the SNP were typed, can be assessed by the MD measure,
23
which can be helpful in interpreting the resulting p values.
When the sample size of the reference panel is small, it
can arise that the case-control sample contains a haplotype
(call it haplotype j), for the typed SNPs, that has an esti-
mated frequency of zero in the reference panel. Thus, the
reference panel lacks information on LD between haplo-
type j and the untyped SNP. As described in subsection,
Mean Model for Haplotypes at Typed Markers in LD with
Untyped SNP, we solve this problem by treating haplotype
j as independent of the untyped SNP. An alternative
approach12 would be to group haplotype j with the closest
haplotype (call it haplotype k), among those having
nonzero estimated frequency in the reference panel, and
then set bpR1jj ¼bpR1jk. This approach assumes that the
untyped SNP has the same conditional distribution given
haplotype j as given haplotype k. In most cases, one would
expect little difference between the two approaches, but if
haplotype j were greatly enriched in the case-control
sample, the results of the two approaches might be some-
what different. This problem could be resolved with larger
reference panels.
Appendix A
We derive the mean model of Equation 2 for haplotypes
ofM from the mean model of Equation 1 for alleles of U.
Let Xi ¼ (ai, xi) be a random variable representing a
randomly chosen combined haplotype from individual i,
where ai is the allele at U and xi is the haplotype at M.
Then our assumption is that P(xi ¼ jjai ¼ m, A) ¼ pjjm, for
m ¼ 0, 1, j ¼ 1, ., H þ 1, i.e., that given the allele at U,
the haplotype at M is conditionally independent of the
phenotype information. Note that E(UijA) ¼ P(ai ¼ 1jA)
and E(YijjA) ¼ P(xi ¼ jjA). Then we have E(YijjA) ¼ E(Ui
jA)P(xi ¼ jjai ¼ 1, A) þ [1 – E(UijA)]P(xi ¼ jjai ¼ 0, A) ¼
E(UijA)pjj1 þ [1 – E(UijA)]pjj0, and the result follows,
where we use the fact that pjj1p þ pjj0(1 – p) ¼ hj and that
pjj1 – pjj0 ¼ hj(p1jj – p)/[p(1 – p)].
Appendix B
Instead of Equation 6, we could use the logistic model
logit

E

Yij jA
 ¼ logithjþ hj
hj

1 hj
 rðFAÞi,
(Equation 11)676 The American Journal of Human Genetics 85, 667–678, Novemwhere all quantities have the same deﬁnitions as in Equa-
tion 6. The quasi-likelihood score test for H0:r ¼ 0 versus
HA:r s 0 based on Equation 11 is identical to that based
on Equation 6, where this test statistic is given in Equation
(8). Conceptually, the advantage of the logistic model (11)
over the linear model (6) is that in the logistic model,
r can be any real number, whereas in the linear model,
r is constrained in a rather complicated way relative to
h ¼ (h1, ., hH)T to ensure that 0% E(YijjA)% 1.
Appendix C
Given the n 3 m matrix A with (i, j)th element aij and the
p 3 q matrix B with (i, j)th element bij, their Kronecker
product, denoted by A 5 B, is the np 3 mq matrix with
block structure
A5B ¼
0@ a11B / a1mB« 1 «
an1B / anmB
1A
np3mq:
Appendix D
We assume that the markers in the setM are tightly linked,
and that, under the null hypothesis, both Hardy-Weinberg
equilibrium and Mendelian inheritance hold. Let Z0
denote Z evaluated under the null hypothesis, r ¼ 0.
Then we have Zij
0 ¼ E0(YijjGi, Gmi, Gﬁ), which can be
explicitly computed, as a function of h and (Gi, Gmi, Gﬁ),
for an outbred, parent-offspring trio, where we allow
some genotypes to be missing. When we plug inbh for h,
we obtain Z evaluated at ðr,hÞ ¼ ð0,bhÞ, which is needed
for Equation 9. We can obtain U ¼ Var0ðZÞ ¼ Var0ðZ0Þ by
ﬁnding the joint conditional distribution of (Gi, Gmi, Gﬁ,
Gj,Gmj,Gfj) for each pair of sampled individuals (i, j), given
the pattern of missing genotypes, where this distribution is
explicitly computed as a function of h, the pedigree infor-
mation, and the pattern of missingness. To obtain Fh, note
that Fh ¼ E0ðvðZ mÞ=vhjAÞ ¼ E0ðvZ0=vhÞ þ 1n5IH ,
where 1n is an n-vector with all entries equal to 1 and IH
is the H 3 H identity matrix. We can explicitly obtain
vZ0/vh from Z0, and the null expectation is obtained
from the joint conditional distribution of (Gi, Gmi, Gﬁ),
given the pattern of missing genotypes, for each sampled
individual i. Finally, consider Fr ¼ E0ðvðZ mÞ=vrjAÞ ¼
E0ðvZ=vrjAÞ þ ðFAÞ5h, where h ¼ ðh1,.,hHÞT . Note
that knowledge of Z0 is not sufﬁcient to obtain E0(vZ/
vrjA). At the same time, it is not necessary to fully specify
Z under the alternative model either. Instead, we need
the ﬁrst-order term of the power series expansion for Z
around r ¼ 0. This ﬁrst-order term is the same for any
two-allele disease model for the untyped SNP, and we use
it to obtain Fr. Note that this is the same assumption
used by Thornton and McPeek (2007)17 to obtain the
MQLSmeanmodel, so we do not need to impose any addi-
tional assumptions to obtain Fr.ber 13, 2009
Acknowledgments
We thank Mark Abney and William Wen for discussion, critical
comments, and help with software implementation; Dan Nicolae,
Matthew Stephens, and Peter McCullagh for discussion and
critical comments; and two anonymous reviewers for critical
comments. This study was supported by National Institutes of
Health grant R01 HG001645. The Framingham Heart Study
(FHS) and the Framingham SHARe project are conducted and sup-
ported by the National Heart, Lung, and Blood Institute (NHLBI)
in collaboration with Boston University. The Framingham SHARe
data used for the analyses described in this manuscript were
obtained through dbGaP (phs000007.v6.p3). This work was not
prepared in collaboration with investigators of the FHS and does
not necessarily reﬂect the opinions or views of the FHS, Boston
University, or NHLBI.
Received: June 18, 2009
Revised: October 6, 2009
Accepted: October 9, 2009
Published online: November 12, 2009
Web Resources
The URLs for data presented herein are as follows:
EntrezGene, http://www.ncbi.nlm.nih.gov/sites/entrez?db¼gene
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